BTK and mantle cell lymphoma: Third, MIPI was established based on overall survival (OS), whereas more accurate prediction of disease relapse upon front-line therapy is in demand given that new therapies, such as bruton tyrosine kinase (BTK) inhibitors and chimeric antigen receptor T cell (CAR-T) therapy tend to play more important roles in the MCL treatment.